De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade (Decrescendo)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04675827 |
|
Recruitment Status :
Recruiting
First Posted : December 19, 2020
Last Update Posted : May 24, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
DECRESCENDO is a multicentre, open-label, dual-phase single-arm phase II de-escalation study evaluating neoadjuvant treatment with 12 administrations of weekly IV paclitaxel 80 mg/m2 (or IV docetaxel 75 mg/m2 every 3 weeks for 4 cycles) combined with subcutaneous (SC) fixed dose combination (FDC) of pertuzumab and trastuzumab (loading dose of 1200 mg pertuzumab and 600 mg trastuzumab, followed by 600 mg pertuzumab and 600 mg trastuzumab) every 3 weeks for 4 cycles.
Surgery will be performed according to local guidelines in all subjects after neoadjuvant treatment.
After surgery, subjects who achieve a pCR (defined as pT0/Tis pN0) will receive adjuvant pertuzumab and trastuzumab FDC SC for additional 14 cycles. Subjects with residual invasive disease will receive salvage adjuvant trastuzumab emtansine (T-DM1, 3.6 mg/kg, IV every 3 weeks) for 14 cycles. In subjects whose residual invasive disease is classified per RCB score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator's discretion, before the 14 cycles of T-DM1.
If histopathological analysis finds that the surgical specimen from a subject with residual disease is ER-positive and/or PR-positive, adjuvant endocrine therapy may be administered concomitantly with study treatment, at the investigator's discretion and according to local guidelines.
Adjuvant radiotherapy will be mandatory after breast-conserving surgery, whereas it will be performed according to local guidelines after mastectomy, and it will be administered concomitantly with pertuzumab and trastuzumab FDC SC in subjects who achieve a pCR, and concomitantly with T-DM1 in subjects with residual invasive disease (after anthracycline-based chemotherapy in subjects assigned to receive this treatment).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HER2-positive Breast Cancer ER-Negative Breast Cancer PR-Negative Breast Cancer Node-negative Breast Cancer | Drug: Pertuzumab and tratuzumab fixed dose combination Drug: Trastuzumab emtansine | Phase 2 |
DECRESCENDO is a multicentre, open-label, dual-phase single-arm phase II de-escalation study evaluating neoadjuvant treatment with 12 administrations of weekly intravenous (IV) paclitaxel 80 mg/m2 (or IV docetaxel 75 mg/m2 every 3 weeks for 4 cycles) combined with subcutaneous (SC) fixed dose combination (FDC) of pertuzumab and trastuzumab (loading dose of 1200 mg pertuzumab and 600 mg trastuzumab, followed by 600 mg pertuzumab and 600 mg trastuzumab) every 3 weeks for 4 cycles.
Surgery will be performed according to local guidelines in all subjects after neoadjuvant treatment.
After surgery, subjects who achieve a pathologic complete response (pCR, defined as pT0/Tis pN0) will receive adjuvant pertuzumab and trastuzumab FDC SC for additional 14 cycles. Subjects with residual invasive disease will receive salvage adjuvant trastuzumab emtansine (T-DM1, 3.6 mg/kg, IV every 3 weeks) for 14 cycles. In subjects whose residual invasive disease is classified per Residual Cancer Burden (RCB) score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator's discretion, before the 14 cycles of T-DM1.
If histopathological analysis finds that the surgical specimen from a subject with residual disease is ER-positive and/or PR-positive, adjuvant endocrine therapy may be administered concomitantly with study treatment, at the investigator's discretion and according to local guidelines.
Adjuvant radiotherapy will be mandatory after breast-conserving surgery, whereas it will be performed according to local guidelines after mastectomy, and it will be administered concomitantly with pertuzumab and trastuzumab FDC SC in subjects who achieve a pCR, and concomitantly with T-DM1 in subjects with residual invasive disease (after anthracycline-based chemotherapy in subjects assigned to receive this treatment).
Patients' tumour intrinsic subtype will be determined based on analysis of the PAM50 gene signature. The PAM50 gene signature, which measures the expression of 50 genes to classify tumours into 1 of 4 intrinsic subtypes (luminal A, luminal B, HER2-enriched, and basal-like), will be assessed in formalin-fixed paraffin embedded (FFPE) samples obtained at baseline. While a tumour biopsy sample must be available prior to enrolment, the PAM50 results will be generated centrally post enrolment and subsequently used to assess the primary endpoint of the study, which is the 3-year recurrence-free survival (RFS) rate in the subpopulation of subjects with HER2-enriched tumours who achieve a pCR after the neoadjuvant phase of the study.
Sub-study:
The flexible care sub-study is an open-label, randomised phase II study to be conducted in selected sites from some of the countries that participate in DECRESCENDO. After completion of neoadjuvant treatment and surgery in the main study, 121 of the subjects who achieved a pCR and thus are assigned to continue treatment with pertuzumab and trastuzumab FDC SC will be randomised at a 1:1 ratio to receive 3 cycles of pertuzumab and trastuzumab FDC SC every 3 weeks in the hospital, followed by 3 cycles in another setting outside the hospital, or to the same treatment starting with 3 cycles outside the hospital followed by 3 cycles in the hospital (treatment cross-over period). After the first 6 cycles of adjuvant treatment, subjects will be asked to choose between continuing treatment (for the remaining 8 cycles, for a total of 14 cycles) within or outside the hospital, according to their preference (treatment continuation period). Subjects can request to change from outside the hospital to in the hospital administration (and vice-versa) at any moment during the treatment continuation period, but not in the treatment cross-over period.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 1065 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Intervention Model Description: | Eligible subjects will first receive neoadjuvant treatment then surgery. After surgery, subjects who achieve a pCR (RCB score at surgery = 0) will receive adjuvant pertuzumab and trastuzumab FDC SC for additional 14 cycles. Those with residual invasive disease (RCB score at surgery ≥ 1) will receive salvage adjuvant T-DM1 for 14 cycles. In subjects with RCB score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator's discretion, before the administration of T-DM1. |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade |
| Actual Study Start Date : | January 17, 2022 |
| Estimated Primary Completion Date : | June 2027 |
| Estimated Study Completion Date : | March 2029 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: RCB = 0
Treatment administration: adjuvant pertuzumab + trastuzumab (P+T) fixed dose combination (FDC) SC for 14 cycles. Sub-study: 121 of the subjects who achieved a pCR (thus assigned to continue treatment with P+T FDC SC) will be randomised at a 1:1 ratio to receive 3 cycles of P+T FDC SC in the hospital, followed by 3 cycles in another setting outside the hospital, or to the same treatment starting with 3 cycles outside the hospital followed by 3 cycles in the hospital (treatment cross-over period). After the first 6 cycles of adjuvant treatment, subjects will be asked to choose between continuing treatment (for the remaining 8 cycles, for a total of 14 cycles) within or outside the hospital, according to their preference (treatment continuation period). Subjects can request to change from outside the hospital to in the hospital administration (and vice-versa) at any moment during the treatment continuation period, but not in the treatment cross-over period. |
Drug: Pertuzumab and tratuzumab fixed dose combination
Treatment administration: adjuvant pertuzumab and trastuzumab fixed dose combination SC for 14 cycles
Other Names:
|
|
Experimental: RCB > 0
Treatment administration:adjuvant T-DM1 for 14 cycles. In subjects whose residual invasive disease is classified per Residual Cancer Burden (RCB) score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator's discretion, before the 14 cycles of T-DM1.
|
Drug: Trastuzumab emtansine
Treatment administration: adjuvant T-DM1 for 14 cycles.
Other Name: Adjuvant T-DM1 |
- 3-year RFS in HER2-enriched subjects who achieve a pCR [ Time Frame: 3 years ]3-year RFS, defined as the time from enrolment until the first occurrence of one of the following events: invasive ipsilateral breast tumour recurrence, local/regional invasive recurrence, distant recurrence, death from breast cancer, death attributable to any cause other than breast cancer, death from unknown cause; in subjects with HER2-enriched, ER-negative/PR-negative, clinically node-negative breast cancers who achieve a pCR after neoadjuvant treatment.
- 3-year RFS in all subjects who achieve a pCR. [ Time Frame: 3 years ]3-year RFS in all subjects who achieve a pCR.
- 5-year RFS in all subjects who achieve a pCR. [ Time Frame: 5 years ]5-year RFS in all subjects who achieve a pCR.
- pCR (in the overall population) [ Time Frame: during procedure ]To assess pCR rates in the overall population and by primary tumour dimension. pCR (in the overall population) is defined as the absence of residual invasive tumour in the breast and axillary lymph nodes (pT0/Tis pN0) at surgery as per the local anatomo-pathological report.
- 3-year RFS (survival rates) [ Time Frame: 3 years ]
In all population, the sub-group analysis according to the pathological response (pCR versus residual disease) and stratified by tumour size (T1 versus T2) for following outcomes:
Survival rates: - 3-year RFS The RFS is defined as the time from enrolment until the first occurrence of one of the following events: invasive ipsilateral breast tumour recurrence, local/regional invasive recurrence, distant recurrence, death from breast cancer, death attributable to any cause other than breast cancer, death from unknown cause
- 3-year invasive disease-free survival (iDFS) (survival rates) [ Time Frame: 3 years ]
In all population, the sub-group analysis according to the pathological response (pCR versus residual disease) and stratified by tumour size (T1 versus T2) for following outcomes:
Survival rates: - 3-year invasive disease-free survival (iDFS) The iDFS is defined as the time from enrolment until the first occurrence of one of the following events: invasive ipsilateral breast tumour recurrence, local/regional invasive recurrence, distant recurrence, death from breast cancer, death attributable to any cause other than breast cancer, death from unknown cause, invasive contralateral breast cancer, second primary invasive cancer (non-breast)
- 3-year distant disease-free survival (dDFS) (survival rates) [ Time Frame: 3 years ]
In all population, the sub-group analysis according to the pathological response (pCR versus residual disease) and stratified by tumour size (T1 versus T2) for following outcomes:
urvival rates: - 3-year distant disease-free survival (dDFS) The dDFS defined as the time from enrolment until the first occurrence of one of the following events: distant recurrence; death from breast cancer; death from non-breast cancer cause; death from unknown cause; second primary invasive cancer (non-breast);
- 3-year overall survival (OS) (survival rates) [ Time Frame: 3 years ]
In all population, the sub-group analysis according to the pathological response (pCR versus residual disease) and stratified by tumour size (T1 versus T2) for following outcomes:
Survival rates: - 3-year overall survival (OS) The OS defined as the time from enrolment until the first occurrence of one of the following events: death from breast cancer, death from non-breast cancer cause, death from unknown cause
- Recurrence-free interval (RFI) (Time) [ Time Frame: 3 years ]
In all population, the sub-group analysis according to the pathological response (pCR versus residual disease) and stratified by tumour size (T1 versus T2) for following outcomes:
Time: Recurrence-free interval (RFI) The RFI is defined as the time interval between enrolment and the occurrence of one of the following events: invasive ipsilateral breast tumour recurrence, local/regional invasive recurrence, distant recurrence; death from breast cancer
- 5-year RFS (survival rates) [ Time Frame: 5 years ]
In all population, the sub-group analysis according to the pathological response (pCR versus residual disease) and stratified by tumour size (T1 versus T2) for following outcomes:
Survival rates: - 5-year RFS The RFS is defined as the time from enrolment until the first occurrence of one of the following events: invasive ipsilateral breast tumour recurrence, local/regional invasive recurrence, distant recurrence, death from breast cancer, death attributable to any cause other than breast cancer, death from unknown cause
- 5-year invasive disease-free survival (iDFS) (survival rates) [ Time Frame: 5 years ]
In all population, the sub-group analysis according to the pathological response (pCR versus residual disease) and stratified by tumour size (T1 versus T2) for following outcomes:
Survival rates: - 5-year invasive disease-free survival (iDFS) The iDFS is defined as the time from enrolment until the first occurrence of one of the following events: invasive ipsilateral breast tumour recurrence, local/regional invasive recurrence, distant recurrence, death from breast cancer, death attributable to any cause other than breast cancer, death from unknown cause, invasive contralateral breast cancer, second primary invasive cancer (non-breast)
- 5-year distant disease-free survival (dDFS) (survival rates) [ Time Frame: 5 years ]
In all population, the sub-group analysis according to the pathological response (pCR versus residual disease) and stratified by tumour size (T1 versus T2) for following outcomes:
Survival rates: - 5-year distant disease-free survival (dDFS) The dDFS defined as the time from enrolment until the first occurrence of one of the following events: distant recurrence; death from breast cancer; death from non-breast cancer cause; death from unknown cause; second primary invasive cancer (non-breast);
- 5-year overall survival (OS)(survival rates) [ Time Frame: 5 years ]
In all population, the sub-group analysis according to the pathological response (pCR versus residual disease) and stratified by tumour size (T1 versus T2) for following outcomes:
Survival rates: - 5-year overall survival (OS) The OS defined as the time from enrolment until the first occurrence of one of the following events: death from breast cancer, death from non-breast cancer cause, death from unknown cause
- Recurrence-free interval (RFI) (time) [ Time Frame: 5 years ]
In all population, the sub-group analysis according to the pathological response (pCR versus residual disease) and stratified by tumour size (T1 versus T2) for following outcomes:
Time: Recurrence-free interval (RFI) The RFS is defined as the time from enrolment until the first occurrence of one of the following events: invasive ipsilateral breast tumour recurrence, local/regional invasive recurrence, distant recurrence, death from breast cancer, death attributable to any cause other than breast cancer, death from unknown cause
- Number of participants experiencing an Adverse Event [ Time Frame: study treatment plus follow-up of 30 days ( Time Frame: Up to approximately 17 months ) ]An adverse event (AE) is any untoward medical occurrence in a subject or clinical investigation subject receiving/undergoing the study treatments (paclitaxel (or docetaxel), pertuzumab and trastuzumab FDC SC, T-DM1, surgery, radiotherapy) and which does not necessarily have a causal relationship with these study treatments. The number of participants who experience an AE (including 1 month of safety follow up) will be presented. The intensity of all AEs will be graded according to the CTCAE version 5 on a five-point scale (Grade 1 to 5).
- Number of participants experiencing an Serious Adverse Event [ Time Frame: through study completion estimated 60 months ]A serious adverse event (SAE) is any untoward medical occurrence that results in any of the following outcomes: Death; Life-threatening; Subject hospitalisation or prolongation of existing hospitalisation; Persistent or significant disability/incapacity; Congenital anomaly/birth defect. The number of participants who experience any SAE while receiving paclitaxel (or docetaxel), pertuzumab and trastuzumab FDC SC, T-DM1, surgery, radiotherapy (including 1 months of safety follow up) with or without the relationship to IMPs will be presented. During survival follow-up, only SAE related to IMPs will be presented.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female.
- Age ≥18 years old.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
- Subjects whose tumour measures ≥15 mm and ≤50 mm, according to clinical staging performed with imaging exams (either mammography, ultrasound or breast magnetic resonance imaging [MRI]).
-
Must have histologically confirmed diagnosis of HER2-positive and ER-negative/PR-negative breast cancer (analysis performed by the local laboratory).
- HER2-positive defined as a score of 3+ in IHC or a positive ISH (ratio of HER2 copy number/chromosome 17 ≥2 or average HER2 copy number ≥6 signals per cell).
- ER-negative/PR-negative defined as estrogen receptor and progesterone receptor nuclear staining <1% by IHC.
Note: patients with micro-invasive carcinoma or ductal carcinoma in situ (DCIS) without invasive disease are not eligible.
-
Subjects with multifocal or multicentric invasive disease are eligible as long as all the biopsiable lesions can be characterised and are confirmed to be HER2-positive and ER and PR negative.
Note: In the case of multifocal or multicentric disease, only the biopsy from the largest lesion should be provided.
- Node-negative disease (N0): no axillary lymph nodes identifiable at ultrasound, or in case of suspect axillary lymph nodes are identified, fine-needle aspiration or core biopsy must be carried out to confirm that axillary status is negative. Axillary micrometastases (i.e., if the greatest diameter of the nodal metastasis in a sentinel node is 0.2 mm or less) are not allowed.
- Serum pregnancy test (for women of childbearing potential) negative within 7 days prior to treatment start.
- Women of childbearing potential must agree to use 1 highly effective non-hormonal contraceptive method with a failure rate of less than 1% per year from the signing of the ICF until at least 7 months after last dose of study drugs; or they must totally abstain from any form of sexual intercourse. Men with a partner of childbearing potential must agree to use condom in combination with a spermicidal foam, gel, film, cream, or suppository, and agreement to refrain from donating sperm, during the course of this study and for at least 7 months after the last administration of study treatment.
-
Adequate bone marrow and coagulation functions as defined below:
- Absolute neutrophil count ≥1500 /µL or 1.5x109/L
- Haemoglobin ≥9 g/dL (blood transfusions to reach these levels of haemoglobin are allowed)
- Platelets ≥100,000/µL or 100x109/L
- International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 ×ULN
-
Adequate liver function as defined below:
- Serum total bilirubin ≤1.5 x ULN. In case of known Gilbert's syndrome ≤3xUNL is allowed
- AST (SGOT) and ALT (SGPT) ≤2.5 x ULN
- Alkaline phosphatase ≤2.5 x ULN
-
Adequate renal function as defined below:
• Creatinine ≤1.5 x UNL or creatinine clearance >60 mL/min/1.73 m2
- Completion of all necessary screening procedures within 28 days prior to enrolment.
- Adequate cardiac function, defined as a left ventricular ejection fraction ≥55% estimated by echocardiogram (ECHO) or multiple-gated acquisition scintigraphy (MUGA).
-
Availability of a pre-treatment tumour biopsy sample as specified below:
- At least one FFPE tumour block must be available for central evaluation. Whenever possible, two FFPE tumour blocks should be available (preferred).
- If a block cannot be provided, 25 unstained FFPE slides of 4 µm thickness from the pre-treatment tumour biopsy must be provided as an alternative. These slides must be freshly cut prior the shipment to the sponsor.
- In either case, the local pathologist must evaluate an H&E stained slide to ensure that the tumour surface is at least 4 mm² and that tumour cellularity is ≥10%.
Note 1: Tumour biopsy must be sent to the central research laboratory as soon as the patient is confirmed by the local investigator to be eligible for the study.
Note 2: the inclusion of the subject is only based on local assessments. A central review of HER2, ER, and PR status will be performed at posteriori for quality control purposes.
- Signed Informed Consent form (ICF) obtained prior to any study related procedure.
-
Subject is willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits and examinations.
Inclusion criterion applicable to FRANCE only:
- Affiliated to the French Social Security System.
Exclusion Criteria:
- Pregnant and/or lactating women.
- Bilateral invasive breast cancer.
- Evidence of metastatic breast cancer: all subjects must have had a CT/MRI scan of the thorax/abdomen/pelvis to rule out metastatic breast cancer prior to enrolment. FDG/PET-CT can be used as an alternative to replace all the exams above. A screening bone scan must have been done if ALP and/or corrected calcium levels were above the institutional upper limits at screening (if PET/CT was used as an alternative imaging exam, a bone scan and/or CT/MRI is not required).
- Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the investigator's opinion, may interfere with completion of the study.
- Previous exposure to any anti-HER2 treatment.
- Concomitant exposure to any investigational products as part of a clinical trial within 30 days prior to enrolment.
- Subject with second primary malignancies diagnosed ≤ 5 years before enrolment in the study. Exceptions are: adequately treated non-melanoma skin cancer, in situ cancer of the cervix, ductal carcinoma in situ of the breast, and any other solid or haematological tumour diagnosed > 5 years before enrolment and for which no chemotherapy and no systemic treatment were necessary, with no evidence of disease recurrence.
- Resting electrocardiogram (ECG) with QTc >470 msec detected on at 2 or more time points within a 24-hour period, or family history of long QT syndrome.
-
Serious cardiac illness or medical conditions including, but not confined to, the following:
- History of NCI CTCAE (v4) Grade ≥ 3 symptomatic congestive heart failure (CHF) or New York Heart Association (NYHA) Class ≥ II
- High-risk uncontrolled arrhythmias (i.e., atrial tachycardia with a heart rate = or > 100/min at rest, significant ventricular arrhythmia [ventricular tachycardia], or higher-grade atrioventricular [AV]-block, such as second degree AV-block Type 2 [Mobitz 2] or third-degree AV-block) - Serious cardiac arrhythmia not controlled by adequate medication, severe conduction abnormality
- Angina pectoris requiring anti-anginal medication
- Clinically significant valvular heart disease
- Evidence of transmural infarction on ECG
- Evidence of myocardial infarction within 12 months prior to randomization
- Poorly controlled hypertension (i.e., systolic > 180 mm Hg or diastolic > 100 mmHg)
- History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias, such as structural heart disease (e.g., severe LVSD, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome.
- Peripheral neuropathy (CTCAE version 5) grade ≥2.
- Major surgery within 14 days prior to enrolment.
- Subject with HIV, Hepatitis B or Hepatitis C infection documented by serology, except for those subjects with a previous exposure to Hepatitis B who developed an effective immune response (HBSAg-negative and anti-HBS-positive).
- Previous allogeneic bone marrow transplant.
- Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (CTCAE grade ≥3).
-
Subjects who received live attenuated vaccines within 14 days before enrolment.
Exclusion criterion applicable to FRANCE only:
- Vulnerable persons according to the article L.1121-6 of the CSP, adults who are the subject of a measure of legal protection or unable to express their consent according to article L.1121-8 of the CSP.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04675827
| Contact: Chloé Velghe | 00322541 ext 7366 | ctsu.decrescendo@bordet.be | |
| Contact: Joséphine Duchateau | 00322541 ext 3976 | ctsu.decrescendo@bordet.be |
Show 87 study locations
| Study Chair: | Martine Piccart, PD, PhD | Jules Bordet Institute |
| Responsible Party: | Jules Bordet Institute |
| ClinicalTrials.gov Identifier: | NCT04675827 |
| Other Study ID Numbers: |
IJB-EBC-Decrescendo-2020 |
| First Posted: | December 19, 2020 Key Record Dates |
| Last Update Posted: | May 24, 2023 |
| Last Verified: | February 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
|
Breast Cancer |
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Trastuzumab Pertuzumab Ado-Trastuzumab Emtansine Maytansine Antineoplastic Agents, Immunological |
Antineoplastic Agents Antineoplastic Agents, Phytogenic Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Immunotoxins Immunoconjugates Immunologic Factors Physiological Effects of Drugs |